Pre-Market Earnings Report for February 9, 2026 : APO, BDX, CNA, DT, CLF, KD, MNDY, CURB, SBH, UVV, ALX, PGY

Multiple U.S. companies are scheduled to report EPS for the quarter ended Dec. 31, 2025 before the open on 02/09/2026, with mixed consensus forecasts: Apollo (APO) $1.91 (+1.06% YoY, P/E 17.06 vs industry 23.40), Becton Dickinson (BDX) $2.82 (-17.78% YoY), Dynatrace (DT) $0.24 (+33.33% YoY, P/E 37.61 vs industry 16.50), Cleveland‑Cliffs (CLF) -$0.62 (improvement +8.82% YoY), Kyndryl (KD) $0.49 (+25.64% YoY), monday.com (MNDY) $0.12 (-76.0% YoY) and Pagaya (PGY) showing a large consensus rebound to $0.57 (+1,525% YoY). The preview also cites analyst coverage counts, recent beat/miss histories and Zacks P/E comparisons — actionable datapoints for stock‑specific positioning but unlikely to move broad markets absent material surprises.

Analysis

Market structure: Earnings slate concentrates idiosyncratic moves rather than a macro shock — winners are scalar: Kyndryl (KD), Sally Beauty (SBH) and fee-stable APO if AUM holds; high-expectation growth names (Dynatrace DT, Pagaya PGY) are binary. Cyclical names (Cleveland‑Cliffs CLF) remain tied to steel/iron‑ore price swings; REITs (ALX, CURB) are rate‑sensitive and will rerate on 10y moves >20bp around earnings. Cross‑asset: a CLF miss risks pressuring iron ore and HRC futures, while insurance/REIT misses can modestly widen BBB spreads and lift dollar safe‑haven flows intraday.

Risk assessment: Tail risks include model/regulatory scrutiny for PGY (consumer credit model audits), a large DT miss given 37x PE, or a sudden commodity shock hitting CLF (20%+ move). Time horizons: immediate (days) expect +/-15–40% idiosyncratic swings on low‑coverage names; short (4–12 weeks) driven by guidance revisions and macro data; long (quarters) driven by secular demand for IT services vs. SaaS re‑rating. Hidden dependencies: many names have one‑to‑three analyst coverage—estimate risk is asymmetric; APO/CNA sensitivity to equity/claim cycles is non‑linear.

Trade implications: Prioritize low‑beta, high‑conviction longs (KD, SBH) and small asymmetric option bets on high‑volatility small‑coverage names (MNDY puts, PGY conditional). Relative value: long KD vs short DT (valuation gap +25–30 PE points) over 6–12 weeks. Use option-sized exposure (0.5–2% portfolio risk) around Feb 9 to cap downside and monetize elevated IV in names that often mean‑revert.

Contrarian angles: Consensus understates execution consistency in KD and downside concentration in single‑analyst PGY/ALX — PGY’s 1,525% EPS jump is plausibly a modeling artifact, not durable. MNDY’s -76% EPS guide is priced for a miss; a beat could produce >50% short‑squeeze. Historical parallels: cyclical rebounds post‑commodity troughs favor CLF on signs of order restarts; unintended consequence — crowded protective puts on small caps could amplify rallies if earnings are clean.

Key Decisions for Investors

• Establish a 2–3% long position in Kyndryl (KD) before 02/09/2026 earnings; set a hard stop at -12% and initial take‑profit at +25% within 6–12 weeks, reassess after guidance commentary.
• Buy a 2% position in Sally Beauty (SBH) shares (or equivalent via 3‑month calls if cheaper); target +30% in 3 months, stop at -15%; rationale: low PE (7.99) and consistent beats.
• Purchase MNDY 30‑day 5% OTM puts sized to 0.5–1% portfolio risk ahead of 02/09/2026; if implied volatility >40% reduce size to 0.25%—exit on 50% gain or within 7–14 days post‑earnings.
• Implement a relative‑value pair: long KD (1.5% portfolio) vs short DT (1.0% portfolio) equalized dollar exposure for 6–12 weeks; unwind if relative P/L hits ±25% or after both report and guidance is digested.
• Make a conditional, small speculative allocation to PGY (0.5% max) only after earnings if revenue growth >30% QoQ and loan book loss rates remain <2%—otherwise avoid due to single‑analyst coverage and model risk.